TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sonnet BioTherapeutics Holdings ( (SONN) ) has shared an update.
On November 18, 2025, Sonnet BioTherapeutics Holdings announced the adjournment of its special meeting of stockholders to December 2, 2025, to allow more time for voting on a proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC. Over 95% of the shares voted so far have supported the business combination, and the company’s board believes the proposals are in the best interest of stockholders. The delay aims to secure the necessary majority approval for the transaction, which includes the listing of HSI’s shares on Nasdaq.
The most recent analyst rating on (SONN) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Sonnet BioTherapeutics Holdings stock, see the SONN Stock Forecast page.
Spark’s Take on SONN Stock
According to Spark, TipRanks’ AI Analyst, SONN is a Underperform.
Sonnet BioTherapeutics Holdings’ overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, negative profitability, and high leverage. Technical analysis indicates a bearish trend with weak momentum, while valuation metrics are unattractive due to a negative P/E ratio and no dividend yield. These factors collectively suggest significant risks and challenges for the company.
To see Spark’s full report on SONN stock, click here.
More about Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company that develops biologic drugs using its proprietary FHAB (Fully Human Albumin Binding) platform. This technology involves a fully human single chain antibody fragment that binds to human serum albumin for targeted delivery to tumor and lymphatic tissues, optimizing the safety and efficacy of immune-modulating biologic drugs.
Average Trading Volume: 889,343
Technical Sentiment Signal: Hold
Current Market Cap: $41.9M
For an in-depth examination of SONN stock, go to TipRanks’ Overview page.